NCT01342380

Pioglitazone and Quetiapine XR Pharmacogenetic Study

Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 42 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.

Conditions

• Bipolar Disorder
• Major Depressive Disorder

Timeline

• Start date: 2011-02-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2011-04-27
• Last updated: 2023-07-18

Locations

1 site across 1 country: United States